Pharmaceuticals

Male Hypogonadism Industry Growth Insights: Revenue Forecast to 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the male hypogonadism market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Male Hypogonadism Market by the end of 2030?

The male hypogonadism market size has experienced robust expansion in recent years. It is anticipated to grow from $3.95 billion in 2025 to $4.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.6%. The historical period’s growth can be ascribed to a rising prevalence of hypogonadism, increased understanding of testosterone deficiency, an expanding aging male population, developments in hormone replacement therapies, and a greater uptake of diagnostic testing by physicians.

The male hypogonadism market is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $5.34 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.4%. This projected growth can be attributed to factors such as the expansion of personalized medicine, the integration of AI in diagnosis and treatment, the proliferation of telehealth services, the increasing adoption of advanced drug delivery systems, and heightened investment in male hormonal research. Significant trends during the forecast period are expected to include personalized testosterone therapy, the development of minimally invasive drug delivery systems, initiatives for male hormonal health awareness, the incorporation of telemedicine into hormonal treatment, and the expansion of chronic disease management services.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

What Drivers Are Shaping Future Opportunities In The Male Hypogonadism Market?

The rising infertility rates are projected to stimulate the growth of the male hypogonadism market moving forward. Infertility describes a condition impacting either the male or female reproductive system, marked by the inability to conceive after 12 months or longer of regular, unprotected sexual intercourse. Male hypogonadism, capable of causing reduced sperm production and infertility, represents one of the possible contributors to male infertility. Consequently, the increasing occurrence of male infertility is expected to drive the expansion of the male hypogonadism market. For example, in February 2023, data from the Office for National Statistics, a UK-based government department, revealed that 31.8% of all live births in England and Wales were to non-UK-born mothers, an increase from 30.3% in 2022, and 37.3% of live births had at least one parent born outside the UK, up from 35.8% in 2022. Thus, an upward trend in the infertility rate is propelling the growth of the male hypogonadism market.

Which Segment Groups Are Influencing The Male Hypogonadism Market?

The male hypogonadism market covered in this report is segmented –

1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types

2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries

3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Subsegments:

1) By Klinefelter’s Syndrome: 47,XXY Syndrome, Other Variants

2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome

3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders

4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders

Which Trends Are Shaping Activity Within The Male Hypogonadism Market?

Leading companies in the male hypogonadism market are prioritizing the development of innovative solutions, such as digital-forward platforms. These platforms are designed to engage patients through telemedicine, furnish educational materials, and streamline access to treatments, thereby revolutionizing care for male hypogonadism by enhancing patient support and therapy accessibility. An example of this is LifeMD, Inc., a US-based provider of virtual primary care services, which launched TestoRx in October 2024. This offering is a direct-to-consumer testosterone replacement therapy telehealth service available under its Rex MD men’s health brand. The program includes an initial virtual consultation, essential blood testing, treatment options covering both testosterone replacement and alternative therapies to boost endogenous hormone production, and continuous telehealth visits for follow-up care.

Who Are The Top-Performing Companies In The Male Hypogonadism Market In Recent Years?

Major companies operating in the male hypogonadism market are Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Antares Pharma Inc., Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, TherapeuticsMD Inc., Viking Therapeutics Inc., Shionogi & Co. Ltd., Ferring Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Which Region Currently Holds The Largest Share Of The Male Hypogonadism Market?

North America was the largest region in the male hypogonadism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Male Hypogonadism Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9969&type=smp

Browse Through More Reports Similar to the Global Male Hypogonadism Market 2026, By The Business Research Company

Male Hypogonadism Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Male Fertility Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-fertility-global-market-report

Human Chorionic Gonadotropin Market Report 2026

https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795